Trial · NCT07895745
Volumetric Adaptive SBRT Versus Conventional Accelerated Radiation Therapy for Early-Stage Glottic Cancer
NCT07895745, Phase 2, Not yet recruiting, University Health Network, Toronto
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Volumetric Adaptive SBRT Versus Conventional Accelerated Radiation Therapy for Early-Stage Glottic Cancer. Trials, record NCT07895745. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07895745
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Volumetric Adaptive SBRT Versus Conventional Accelerated Radiation Therapy for Early-Stage Glottic Cancer
- NCT number
- NCT07895745
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 150 participants, estimated
- Lead sponsor
- University Health Network, Toronto
- Conditions
- Glottic Carcinoma
- Interventions
- Long course accelerated fractionation radiation therapy, Adaptive stereotactic body radiation therapy
- First posted
- 2026-10-26
- Last updated
- 2026-10-26
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Local Control (LC) | From randomization until local failure or last follow-up (up to 2 years) | Local control (LC), defined as the time from randomization to the date of local failure, after comprehensive clinical examination and radiographic evaluation. |
| Secondary | Locoregional Failure (LRF) | 2 Years | |
| Secondary | Distant Metastasis (DM) | 2 Years | |
| Secondary | Laryngectomy free survival (LFS) | 2 Years | |
| Secondary | Disease free survival (DFS) | 2 Years | |
| Secondary | Overall survival (OS) | 2 Years | Overall survival (OS) is defined as the time from the date of randomization to the date of death due to any cause. |
| Secondary | Physician-assessed toxicities | 2 Years | National Cancer Institute (NCI) Common Terminology Criteria of Adverse Events (CTCAE) V.6, where higher grades indicate greater severity of toxicity. |
| Secondary | Patient-reported toxicities | 2 Years | Patient Reported Outcomes - Common Terminology Criteria of Adverse Events (PRO CTCAE) V.1, where higher scores indicate greater symptom burden and worse patient-reported toxicity. |
| Secondary | Quality of life (QOL) (UW-QOL) | 2 years | Head and Neck Cancer Specific QOL \[University of Washington Quality of Life Questionnaire (UW-QOL)\], where higher scores indicate a better quality of life. |
| Secondary | Quality of life (QOL): Voice Handicap Index (VHI) | 2 Years | Voice Handicap Index (VHI): a patient-reported questionnaire that assesses the functional, physical, and emotional impact of voice disorders, where higher scores indicate greater voice-related handicap. |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07895745
GET https://conductscience.org/api/trials/v1/NCT07895745/registered